Phosphagenics initiates US clinical trial for dermatological product

This trial is claimed to be the company’s first clinical trial to take place in the US and denotes the commencement of the company’s planned expansion into targeted, non-systemic delivery of drugs. According to the American Journal of Dermatology, retinoic acid is prescribed most often as the topical treatment of choice for acne.

Harry Rosen, president & CEO of Phosphagenics, said: “A new formulation with the ability to deliver greater absorption of retinoic acid, reduce irritation and dryness and limit systemic circulation would significantly increase practitioners’ flexibility in prescribing the product. It would enable physicians to prescribe greater doses of retinoic acid and/or maintain current dosing while achieving improved efficacy and substantially limiting adverse effects.”